Press release
Global Spasticity Therapeutics Poised for Major Evolution: DelveInsight Reveals Analysis of 12+ Pipeline Candidates
Spasticity Therapeutics
Stay ahead of emerging trends in Spasticity treatment. Access DelveInsight's in-depth Spasticity Pipeline Report to explore novel therapies, prominent developers, and shifting dynamics within the treatment landscape. Discover more here - Spasticity Pipeline Outlook: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Spasticity Pipeline Report
• July 2025: Celgene initiated a Phase II clinical trial to assess the safety, effectiveness, and tolerability of three oral dose levels of BMS-986368, a dual FAAH/MAGL inhibitor, for treating Spasticity in patients with Multiple Sclerosis under the BALANCE-MSS-1 study.
• June 2025: Ipsen commenced a dose-escalation study of IPN10200 to evaluate its pharmacodynamic characteristics and establish the dose that offers the optimal balance between efficacy and safety in adults with upper limb spasticity.
• The report presents a robust and evolving pipeline landscape, featuring more than 10 active companies advancing over 12 innovative therapeutic programs for Spasticity.
• Key industry participants include Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd., Ipsen, Motor Pharma, Lundbeck A/S, among others.
• Prominent emerging therapies highlighted in the report include IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, and ultrasound-guided Meditoxin®.
Explore breakthroughs redefining Spasticity management. Gain full access to the clinical pipeline and ongoing study insights here: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Spasticity Understanding: An Overview
Spasticity is a neurological motor condition marked by heightened muscle tone, rigidity, and involuntary muscle contractions caused by impaired signaling between the brain, spinal cord, and muscles. It frequently develops as a consequence of neurological disorders such as stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, and spinal cord injury. Persistent muscle stiffness can significantly restrict movement, hinder daily functioning, and diminish quality of life. Clinical severity ranges from mild muscle tightness to severe, painful spasms. Current management strategies include physiotherapy, oral pharmacological agents, botulinum toxin injections, and advanced options like intrathecal drug delivery. Ongoing research efforts focus on creating more precise, durable, and effective treatment approaches.
Emerging Drug Profiles in the Spasticity Pipeline
MELPIDA - Elpida Therapeutics SPC
Elpida Therapeutics SPC, a Social Purpose Corporation, specializes in developing gene therapies for ultra-rare pediatric neurological disorders. Its lead candidate, Melpida, is an AAV9-based gene therapy designed to deliver a functional AP4M1 gene via intrathecal administration for the treatment of SPG50. Following the completion of Phase I/II trials, the therapy has received FDA approval to advance into a Phase III study involving eight pediatric patients starting in August 2024. In addition to SPG50, Elpida is progressing gene therapy programs targeting disorders such as CMT4J. Melpida is currently in Phase III development.
SL-1002 - Saol Therapeutics
SL-1002 is a proprietary chemoneurolytic injectable therapy being investigated for the treatment of adult limb spasticity and pain associated with knee osteoarthritis. The candidate is presently undergoing Phase II clinical evaluation for Spasticity.
IPN-10200 - Ipsen
IPN-10200 is a next-generation, long-acting botulinum neurotoxin type A (mrBoNT/A) engineered to provide extended therapeutic duration. Delivered via intramuscular injection, the therapy is in Phase I/II clinical development for aesthetic indications such as glabellar and forehead lines, as well as for adult upper limb spasticity following stroke or traumatic brain injury. Ongoing studies are focused on assessing its safety, clinical benefit, and optimal dosing strategy.
What the Spasticity Pipeline Report Includes
• Detailed profiles of companies engaged in Spasticity drug development, along with the number of active programs under each organization.
• Categorization of pipeline assets by development stage, including early-, mid-, and late-stage programs.
• Overview of ongoing as well as paused or discontinued development efforts.
• Comprehensive analysis of therapies based on development phase, administration route, mechanism of action, molecular structure, and use as monotherapy or combination therapy.
• In-depth insights into strategic collaborations, licensing deals, and financial activities shaping pipeline advancement.
Uncover deeper insights into innovative programs driving progress in Spasticity care.
Explore the complete report - Spasticity Unmet Needs: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Companies Advancing the Spasticity Pipeline
Elpida Therapeutics SPC | Saol Therapeutics | Revance Therapeutics Inc. | BlackfinBio Ltd | Ipsen | Motor Pharma | Lundbeck A/S | Others
Spasticity Pipeline Segmentation by Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Spasticity Pipeline Segmentation by Molecule Type
• Monoclonal Antibodies
• Small Molecules
• Peptides
Gain actionable intelligence on upcoming therapies and critical development milestones.
Explore Spasticity market drivers, challenges, and future projections: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Spasticity Pipeline Report
• Geographic Coverage: Global
• Key Companies: Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S, and others
• Key Pipeline Assets: IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, ultrasound-guided Meditoxin®, among others
• Therapeutic Approaches: Monotherapy, Combination therapy, and Hybrid regimens
• Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
Identify the leading innovators and breakthrough programs shaping Spasticity drug development.
Explore emerging therapies and the companies defining the future of care: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Spasticity Therapeutics Poised for Major Evolution: DelveInsight Reveals Analysis of 12+ Pipeline Candidates here
News-ID: 4346905 • Views: …
More Releases from DelveInsight Business Research
Biliary Tract Cancer Market: Growth Momentum Across 7MM to 2034 - DelveInsight
DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer…
Behcet's Disease Market: Expanding Revenue Landscape to 2034 - DelveInsight
DelveInsight's "Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Behcet's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet's Disease Market Forecast
https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Anaphylaxis Market: Rapid Increment Driven by Innovation - DelveInsight
DelveInsight's "Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Anaphylaxis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anaphylaxis Market Forecast
https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Anaphylaxis…
Tendonitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight
The Tendonitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tendonitis pipeline products will significantly revolutionize the Tendonitis market dynamics.
DelveInsight's "Tendonitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France,…
More Releases for Spasticity
Spasticity Market: Rapid Growth & Investment Outlook to 2032 - DelveInsight
The Spasticity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.
DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction
Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion.
According…
Spasticity Drugs Market Segments, Growth and Trends by Forecast by 2031
The report is segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), Route of Administration (Oral, Intramuscular, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Get Sample Copy -https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10831
Major Companies operating in the Spasticity Drugs Market are:
Ipsen Pharma
Allergan
Acorda Therapeutics,…
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits.
Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Spasticity Drugs Market are:
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
Contact Us:
If you have any queries about this report or if…
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now
The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource…
